Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

HHALOZYME THERAPEUTICS, INC.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
H

HALOZYME THERAPEUTICS, INC.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • History
  • News
  • Insider Transactions
Loading financials
Income statement income statement flow. Revenue $481M. Net result $229.91M.

Income statement revenue $481M (+47.7% YoY).Operating income $287.65M (+42.1% YoY).Pre-tax result $284.9M (+39.0% YoY).Net result $229.91M (+39.2% YoY).

  • Bulk R Hu PH20: $59.62M (+156.2% YoY)
  • Device Licensing And Development: $2.47M (-39.4% YoY)
  • Device Partnered Products: $14.58M (+23.7% YoY)
  • Event Based Development And Regulatory Milestone And Other Fees: $5.71M (-76.7% YoY)
  • Proprietary Products Sales: $55.43M (+19.3% YoY)
  • Royalty: $307.7M (+49.6% YoY)
  • Upfront Fees: $35.5M
  • Amortization of intangibles: $29.51M (+66.2% YoY)
  • Research and development: $27.66M (+57.7% YoY)
  • Selling, general and administrative: $57M (+37.0% YoY)
  • Other expense: $2.75M
  • Income tax expense: $54.99M (+38.2% YoY)